Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Couselo

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Revista Espanola De Oncologia|January 1, 1982
[Osteosarcoma: 2d malignant tumor following treatment with radiotherapy]J M Couselo Sánchez, J Varela Durán, A Bao Corral, et al.
Anales Espanoles De Pediatria|June 1, 1983
[Neutropenia and glycogenosis type IB]J M Couselo Sánchez, M López Rivas, E Pérez Becerra, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 5, 2016
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?A Di Cataldo, A Agodi, J Balaguer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Revista Espanola De Oncologia|January 1, 1982
[Osteosarcoma: 2d malignant tumor following treatment with radiotherapy]J M Couselo Sánchez, J Varela Durán, A Bao Corral, et al.
Anales Espanoles De Pediatria|June 1, 1983
[Neutropenia and glycogenosis type IB]J M Couselo Sánchez, M López Rivas, E Pérez Becerra, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 5, 2016
Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?A Di Cataldo, A Agodi, J Balaguer, et al.
Pageof 4